31results about "C-reactive protein" patented technology

Compositions and methods are provided for the treatment of fibrosis related disorders utilizing the ratio of the concentration of serum amyloid P(SAP) to C-reactive protein (CRP) in a patient. The methods may further comprise determining the R131 / H131 polymorphism of FcγRIIA. Diagnostic methods are also provided.

An object of the present invention is to provide a method and a reagent for measuring the subject substances containing high concentration of C-reactive protein without dilution while avoiding prozone phenomenon. C-reactive protein is measured with a compound having a phosphrylcholine group and a cationic group shown by the general formula (I) [in the formula (I), where R1, R2 and R3 stand for a hydrogen atom, substituted or non-substituted alkyl, or substituted or non-substituted alkenyl, and X- stands for an inorganic anion or an organic anion) and an antibody to C-reactive protein. Or, C-reactive protein is measured with a surface active agent having a phosphorylcholine group, a surface active agent having a cationic group shown by the formula (II) [Y1 stands for a hydrophobic group, and R1, R2 and R3 stand for a hydrogen atom, substituted or non-substituted alkyl, or substituted or non-substituted alkenyl], and an antibody to C-reactive protein. As an antibody to C-reactive protein, an antibody carried by a water-insoluble carrier such as latex made from polystyrene is preferable.

The use of inhibitors of long pentraxin PTX3 for the preparation of a medicament for the prevention and treatment of autoimmune diseases and of degenerative diseases of bone and cartilage is described.

The present invention provides methods and systems to accurately detect and measure in a biological sample from a patient, endogenous antibodies, e.g., IgA, to inflammatory proteins, which antibodies are useful as diagnostic markers for inflammatory conditions, including bowel disease (IBD), in patients. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.

An aptamer specifically binding to C-reactive protein (CRP) is provided. The aptamer includes a following nucleotide sequence: 5′-angngggngnntgnnt-3′, wherein n is a nucleotide selected from a, t, c and g.

Described herein are homing polypeptides that home to atherosclerotic plaque(s) in mammals and nucleic acids that encode such polypeptides. Also described are methods for detecting and treating conditions or disorders associated with, or characterized, by elevated levels of homing polypeptides that home to atherosclerotic plaque and / or vulnerable plaque.

The present invention provides a biomarker for detecting and diagnosing polypoidal choroidal vasculopathy (PCV) of human eyes, including levels of hyperhomocysteinemia that are identified, wherein elevated levels of hyperhomocysteinemia are highly associated with PCV of the human eyes. In addition, the present invention further provides a method for detecting and diagnosing PCV of the human eyes.

The application provides methods for determining a patient's risk for developing fibrosis or a fibrosis-related disorder. Concentrations of C reactive protein (CRP) and serum amyloid protein (SAP) are measured from a biological sample to determine the SAP-to-CRP ratio. This ratio can then be compared with one or more SAP-to-CRP reference ratios to determine a patient's risk for developing a fibrosis related disorder. The diagnostic methods can also be used to determine the severity of fibrosis in a patient afflicted with such a disease. Furthermore, methods for treating patients having a fibrosis-related disorder are provided. For example, a patient that has a lower SAP-to-CRP ratio than one or more reference values may be treated with an SAP agonist and / or CRP antagonist to treat or prevent a fibrosis disorder. The methods may further comprise determining the R131 / H131 polymorphism of FcγRIIA as a risk factor for developing fibrosis or a fibrosis-related disorder.

The present invention relates to a method for diagnosing the degree of arteriosclerotic stenosis in a subject including determining the amount of CRP or LPa in a sample of the subject and comparing the determined amount to a reference whereby the degree of arteriosclerotic stenosis is determined. The present invention also contemplates a method for identifying a subject in need of prevention or therapy of arteriosclerosis. Further, devices and kits are encompassed for carrying out the methods.

The invention belongs to the biotechnological field, and provides a polypeptide. The polypeptide includes two dominant antigen epitopes of the recombinant canine C-reactive protein (CRP). The polypeptide is coupled with the KLH protein for enhancing the immune effect. The invention provides a canine CRP recombinant protein. The canine CRP recombinant protein mainly includes the two dominant antigen epitopes. Specific to the aim of increasing the yield of the recombinant protein in a prokaryotic expression system, the recombinant protein amino acid sequence is converted into a corresponding nucleotide sequence by using an escherichia coli preferred codons, the nucleotide sequence is subjected to chemical synthesis, and the recombinant protein expression vector is built. The invention further relates to the preparation of the recombinant protein mono-clone antibody, the mono-clone antibody is prepared by antigen immunization, cell fusion and a plurality of screening, the mono-clone antibody is purified, the fluorescent microsphere is marked respectively, the best mono-clone pair determined through orthogonal experiment, the recombinant canine C-reactive protein can be applied to diagnosis of inflammation.

Disclosed are a highly efficient method for production of heterologous proteins performed by utilizing microorganisms, as well as fusion proteins, and an antiserum. The method includes a method for production of a protein (A) in the form of a fusion protein, comprising the steps of (a) preparing a DNA which codes for a fusion protein comprising the peptide chain forming the protein (A) and the C-terminal peptide or its fragment (B) of the Cry proteins produced by Bacillus thuringiensis, and (b) introducing the DNA into a host bacterium to transform the same, and (c) allowing the fusion protein to be expressed in the transformed host bacterium, as well as a method for production of the protein (A) itself comprising a further step of removing the peptide chain (B) from the fusion protein obtained.

The purpose of the present invention is to provide: a polydimethylsiloxane substrate obtained through the bonding of peptides having an affinity for polydimethylsiloxane (PDMS); a method for immobilizing a target protein on the polydimethylsiloxane substrate; peptides having an affinity for PDMS; polynucleotides for coding the peptides having an affinity for PDMS; and vectors and the like that use the polynucleotides. A polydimethylsiloxane substrate obtained through the bonding of peptides having an affinity for polydimethylsiloxane, said peptides comprising (1a) or (1b) below or fragments thereof. (1a) A peptide comprising an amino acid sequence represented by at least one sequence selected from the group consisting of SEQ ID Nos. 1 to 9. (1b) A peptide having an affinity for polydimethylsiloxane, and comprising an amino acid sequence in which one or a plurality of amino acids have been deleted, substituted and / or added in the amino acid sequence of (1a).

The invention discloses a composite quality control product based on multiple diagnostic marker-specific epitope polypeptide molecules linked by ferritin nanoparticle carriers and a preparation method thereof. Through antibody detection and epitope analysis techniques, most of the The dominant epitope of the diagnostic marker protein is located, and then linked to the ferritin molecule by connecting esters to form a "Fer-Linker-Epitope Peptide" complex, and the synthetic gene sequence of the complex is transferred into the prokaryotic large intestine through a specific vector Bacillus recombinant expression, so that the composite antigen (quality control product) containing the dominant epitope polypeptide molecules of multiple diagnostic markers can be detected by multiple diagnostic reagents at the same time. The quality control product of the invention has high detection efficiency, low cost and excellent stability, and can be stored stably for a long time under the condition of 2-8°C.

The invention belongs to the technical field of protein purification, and discloses a phospholipid organic polymer whole material and a preparation method and application thereof. The method comprisesthe steps that phospholipid monomeric compound, crosslinking agent, porogen and initiator are mixed and then poured into a container after ultrasonic dissolving and deaeration are conducted, aggregation reaction is conducted under the temperature of 40-70 DEG C or under ultraviolet irradiation, and the phospholipid organic polymer whole material is obtained. The phospholipid organic polymer wholematerial has the advantages of high reproducibility, good biocompatibility and protein nonspecific adsorption resistance, and the existing defects of a traditional CRP purified material are effectively overcome. According to the material, by taking the phospholipid organic polymer whole material as an absorbent purifying standard protein mixed sample or an actual sample, CRP proteins with high purity can be obtained simply by one purifying strategy, the operation is easy, and the recovery rate is close to 100%.

The invention relates to the use of a citrate solution for affinity-chromatographic removal of C-reactive protein (CRP) from biological fluids, wherein the CRP is affinity-chromatographically removed using (Ca2+-dependent) binding of CRP to a column material functionalized with ω-phosphonooxyalkyl ammonium groups and / or with ω-ammoniumalkoxy-hydroxy-phosphoryloxy groups.

The invention relates to the use of a citrate solution for affinity-chromatographic removal of C-reactive protein (CRP) from biological fluids, wherein the CRP is affinity-chromatographically removed using (Ca2+-dependent) binding of CRP to a column material functionalized with ω-phosphonooxyalkyl ammonium groups and / or with ω-ammoniumalkoxy-hydroxy-phosphoryloxy groups.